Noticias de TARS_US

Noticias del mercado

Últimas noticias sobre TARS_US — 130 novedades recientes. Análisis, balances, opiniones y cobertura de prensa.

Ticker: TARS_US ✕ 130 resultados
16/04/2026 TARS_US — MarketBeat
Tarsus Pharmaceuticals (NASDAQ:TARS) Stock Price Down 5.9% - Here's What Happened
14/04/2026 TARS_US — Seeking Alpha
Tarsus Pharmaceuticals: Marketing Spend Bears Fruit, Pipeline Progresses (NASDAQ:TARS)
13/04/2026 TARS_US — MarketBeat
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Given Average Rating of "Moderate Buy" by Brokerages
12/04/2026 TARS_US — Stock Traders Daily
(TARS) Volatility Zones as Tactical Triggers
06/04/2026 TARS_US — MSN ES ← EN
Tarsus recibirá un hito de 15 millones de dólares después de que China apruebe la terapia ocular TP-03
06/04/2026 TARS_US — Newser
Is Tarsus Pharmaceuticals (TARS) Stock Consolidating | Price at $71.50, Up 1.97% - Popular Market Picks
06/04/2026 TARS_US — Newser
Is Tarsus Pharmaceuticals (TARS) Stock Consolidating | Price at $71.50, Up 1.97% - Community Pattern Alerts
06/04/2026 TARS_US — Newser
Is Tarsus Pharmaceuticals (TARS) Stock Consolidating | Price at $71.50, Up 1.97% - Support Bounce
06/04/2026 TARS_US — laocai.gov.vn
Is Tarsus Pharmaceuticals (TARS) Stock Consolidating | Price at $71.50, Up 1.97% - Social Investment Platform
06/04/2026 TARS_US — sonla.gov.vn
Is Tarsus Pharmaceuticals (TARS) Stock Consolidating | Price at $71.50, Up 1.97% - Insider Buying
04/04/2026 TARS_US — MarketBeat
Tarsus Pharmaceuticals (NASDAQ:TARS) Upgraded to Buy at Wall Street Zen
01/04/2026 TARS_US — Stock Traders Daily
Price-Driven Insight from (TARS) for Rule-Based Strategy
31/03/2026 TARS_US — GlobeNewswire
Tarsus Doses First Participant in Calliope, A Phase 2
31/03/2026 TARS_US — GuruFocus
Tarsus Pharmaceuticals (TARS) Initiates Phase 2 Trial for Lyme D
31/03/2026 TARS_US — Yahoo Finance
Tarsus Doses First Participant in Calliope, A Phase 2 Clinical Trial of TP-05 (lotilaner), a Novel Investigational Oral Tablet for the Potential Prevention of Lyme Disease
31/03/2026 TARS_US — GlobeNewswire
Tarsus Doses First Participant in Calliope, A Phase 2 Clinical Trial of TP-05 (lotilaner), a Novel Investigational Oral Tablet for the Potential Prevention of Lyme Disease
27/03/2026 TARS_US — Stock Titan
Vanguard Realignment: Tarsus (NASDAQ: TARS) Ownership Reported as 0% by Parent
24/03/2026 TARS_US — Stock Titan
Tarsus Pharmaceuticals (TARS) COO sells 2,989 shares in planned trade
23/03/2026 TARS_US — Yahoo Finance
TP-03 (lotilaner ophthalmic solution) 0.25% Now Approved in China for the Treatment of Demodex Blepharitis, Triggering a $15M Milestone Payment to Tarsus
23/03/2026 TARS_US — Investing.com
Tarsus earns $15M milestone on China approval of eye drug

Página 4 de 7

keyboard_arrow_up